GENERAL COMMENTS
This paper is an interesting follow-up on reference #13, which described an increased risk of development of RA in HCV-infected persons. The findings suggest that treatment of HCV with interferonbased therapy may reduce the risk of RA. I have some concerns as follows: 1) HCV infection can cause a chronic arthritis that looks much like RA and could potentially fulfill criteria for RA, but is distinct in the lack of ACPAs and erosions. This is not RA, though it is similar. In addition, the ACR criteria require exclusion of other similar conditions and it is not clear if that condition is met for all cases.
2) The incidence of RA overall seems very high in both the treated and untreated cohort. Could this be because it is not RA? 3) Although one paper is cited (ref 37) suggesting that interferon might improve existing RA, the general consensus is that interferonbased therapy can potentially induce/worsen autoimmune diseases (and this is noted in the introduction with multiple references cited). For this reason, it is often avoided in individuals with autoimmune disease. Is it possible that the lower rate of RA in the treated group could be related to selection of individuals for treatment who are at Figure 1 and Figure 2 is suboptimal, further picture processing would ensure an higher definition in order to make them clear to read". To address the Reviewer's concern, we provide higher definition of figures 1 and 2 (page 27).
Reply to Reviewer 2 1. Response to "HCV infection can cause a chronic arthritis that looks much like RA and could potentially fulfill criteria for RA, but is distinct in the lack of ACPAs and erosions. This is not RA, though it is similar. In addition, the ACR criteria require exclusion of other similar conditions and it is not clear if that condition is met for all cases." Although RA shares similar feature of arthralgia with HCV infection, the accuracy and validity of RA diagnosis is of less concern because the NHI Administration selected at least two experienced and qualified rheumatologists to validate RA diagnosis by reviewing patients' medical charts, laboratory data and x-ray images before issuing a catastrophic illness certificate (Ref 4, 5, 11) . Thus, every RA patient who was registered in the Registry of Catastrophic Illness Patient Database fulfilled the American College of Rheumatology criteria for the classification of RA. The diagnosis of RA by ICD-9 code has been applied in previous NHIRD-based nationwide cohort studies (Ref 4, 5, 11) . To address the Reviewer's concern, we add these statements in the revised manuscript (page 18, lines 5-10).
2. Response to "The incidence of RA overall seems very high in both the treated and untreated cohort. Could this be because it is not RA?" Reference 11 (Su et al.) showed that HCV(+) subjects had a higher incidence of RA than HCV(-) subjects. In the present study, we showed that treated HCV(+) subjects had a lower incidence of RA than untreated HCV(+) subjects. The study population in the present study is HCV(+) population. Thus, the incidence of RA overall seems higher in both the treated and untreated cohorts.
3. Response to "Although one paper is cited (ref 37) suggesting that interferon might improve existing RA, the general consensus is that interferon-based therapy can potentially induce/worsen autoimmune diseases (and this is noted in the introduction with multiple references cited). For this reason, it is often avoided in individuals with autoimmune disease. Is it possible that the lower rate of RA in the treated group could be related to selection of individuals for treatment who are at lower risk of autoimmune disease?" Figure 1 showed that HCV(+) patients with diagnosis of autoimmune rheumatic diseases prior to diagnosis of HCV were excluded. Thus, HCV(+) patients enrolled in the present study had no autoimmune diseases at baseline.
4. Response to "Introduction 2nd paragraph states that HCV infection can induce an anti-viral immune response, then mentions extra-hepatic manifestations. This is typically thought to be due to viral infection of B cells, not an anti-viral immune response." We heartily thank the Reviewer for the correction. To address the Reviewer's concern, we made a correction in the revised manuscript (page 6, lines 13-14; Ref 8).
5. Response to "Introduction 3rd paragraph states that interferon-based therapy is considered a mainstay of HCV treatment. This is no longer true, at least when direct acting antiviral agents are available." Although interferon-free regimens composed of direct acting antiviral agents are now becoming a new paradigm (Ref 12), interferon-based therapy plus ribavirin has been widely used as the regimen of choice for a decade, and attains an eradication rate over 70% among treatment-naïve patients in Taiwan and creates excellent therapeutic responses in Asian countries where interleukin-28B genotypic polymorphism is prevalent (Ref 13-15) . Moreover, reimbursement for some direct acting antiviral agents in Taiwan's NHI program begins in 2017 and the present study used the LHID2005 (a subset of NHIRD) in 1997-2012. To address the Reviewer's concern, we make a correction in the revised manuscript (page 7, lines 1-6).
Response to "Methods p.10-what proportion of eligible people do apply for the Catastrophic
Illness registration card? What criteria are there for approval as RA? Could these people have HCV arthritis and not RA? It would be very helpful if ACPA results were available." In Taiwan, insured persons with major diseases can apply for a catastrophic illness certificate from the NHI Administration that grants exemption from copayment for healthcare. The issuance of catastrophic illness certificates was validated by at least 2 specialists, based on careful examination of the medical records, laboratory studies, and imaging studies. Only individuals who meet the diagnostic criteria for major diseases are issued a catastrophic illness certificate. RA is statutorily included in the catastrophic illness category. Thus, all RA patients who were obtained in the Registry of Catastrophic Illness Patient Database, a subpart of the NHIRD, fulfilled the American College of Rheumatology criteria for the classification of RA. Although RA shares similar feature of arthralgia with HCV infection, the accuracy and validity of RA diagnosis is of less concern because the NHI Administration selected at least two experienced and qualified rheumatologists to validate RA diagnosis by reviewing patients' medical charts, laboratory data (eg. ACPA results), and x-ray images before issuing a catastrophic illness certificate. In the present study, all cases of RA were obtained from the Registry of Catastrophic Illness Patient Database. To address the Reviewer's concern, we add the complete statements in the revised manuscript (page 10, lines 16-19; page 11, lines 1-6).
7. Response to "Results p. 12, what are enrollee categories 1 and 3?" Enrollee category (EC) was used as a proxy measure of socioeconomic status to minimize environmental impact. In the NHIRD, EC was classified as 4 subgroups: EC1 (highest socioeconomic status, eg, civil servants, full-time or regularly paid personnel in governmental agencies and public schools), EC2 (employees of privately owned enterprises or institutions), EC3 (self-employed, other employees or paid personnel, and members of the farmers or fishers associations), or EC4 (lowest socioeconomic status, eg. substitute service draftees, members of low-income families, and veterans) (Ref 30) . To address the Reviewer's concern, we add the complete statements in the Methods section of the revised manuscript (page 11, lines 18-19; page 12, lines 1-5).
8. Response to "Discussion 1st paragraph states this study is "the first to identify which HCV-infected persons are more likely to benefit from IBT." This is not a true statement in the broad sense, as many studies have evaluated factors associated with benefit from IBT." To address the Reviewer's concern, we omit this statement in the revised manuscript (page 14, line 16).
9. Response to "Discussion 1st paragraph, what does it mean that the benefit "persisted" in HCVinfected men and men <60?" To address the Reviewer's concern, we make a revision in the revised manuscript (page 14, line 19; page 15, line 1).
10. Response to "Discussion p. 17 gives more information about the catastrophic illness databasesome of this should go in the Methods section." To address the Reviewer's concern, we add the complete statements in the Methods section of the revised manuscript (page 10, lines 16-19; page 11, lines 1-6).
VERSION 2 -REVIEW

REVIEWER
Elizabeth Ferucci ANTHC, USA REVIEW RETURNED 17-Mar-2018
GENERAL COMMENTS
The manuscript has improved significantly and has addressed most comments adequately. It appears the authors still did not address the possibility of HCV induced inflammatory arthritis mimicking RA (this is NOT the same as HCV and arthralgia, but actually has RF+, associated joint inflammation, and looks like RA, but CCP Ab is negative and erosions do not develop). This needs to be addressed as a limitation of the study. HCV associated arthritis could meet criteria for RA but the criteria for RA also include the requirement to exclude other causes, so technically it should not be categorized as RA. This remaining limitation needs to be addressed. One way would be to present the % of people with RA who are CCP Ab positive, and if high, would support the hypothesis that it is truly RA rather than HCV-associated inflammatory arthritis.
VERSION 2 -AUTHOR RESPONSE Reply to Reviewer 2 1. Response to "It appears the authors still did not address the possibility of HCV induced inflammatory arthritis mimicking RA (this is NOT the same as HCV and arthralgia, but actually has RF+, associated joint inflammation, and looks like RA, but CCP Ab is negative and erosions do not develop). This needs to be addressed as a limitation of the study. HCV associated arthritis could meet criteria for RA but the criteria for RA also include the requirement to exclude other causes, so technically it should not be categorized as RA. This remaining limitation needs to be addressed. One way would be to present the % of people with RA who are CCP Ab positive, and if high, would support the hypothesis that it is truly RA rather than HCV-associated inflammatory arthritis".
To address the Reviewer's concern, we list this point as a limitation and add a statement and four new references in the revised manuscript (page 18, page 19, page 27, page 28, .
Thank you heartily for your invaluable opinions on this paper. We are deeply honored by the time and efforts that you had spent in reviewing and revising this manuscript. By incessantly reviewing and revising our texts, we are spurred to read more and learn more from your comments.
VERSION 3 -REVIEW
REVIEWER
Elizabeth Ferucci ANTHC, USA REVIEW RETURNED 14-Apr-2018
GENERAL COMMENTS
Addresses the final reviewer comments adequately.
